Summit Therapeutics (SMMT) Gains from Investment Securities (2020)
Summit Therapeutics (SMMT) posted Gains from Investment Securities of -$1000.0 for Q4 2020, little changed on a QoQ basis from -$1000.0 in Q3 2020.
Summit Therapeutics (SMMT) Gains from Investment Securities (2020) Analysis & Trends
Summit Therapeutics' Gains from Investment Securities history runs 1 years deep, the most recent figure standing at -$1000.0 for Q4 2020.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$1000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2021 was -$2000.0 (changed N/A YoY) and the FY2020 annual result came in at -$102000.0, down 5200.0% from the prior year.
- Gains from Investment Securities was -$1000.0 for Q4 2020 at Summit Therapeutics, roughly flat from -$1000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at -$1000.0 in Q3 2020 and bottomed at -$1000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Summit Therapeutics | 10.60 Bn | 10.00 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -1,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |